ArticleFrontiers in microbiology2021
Characterization of IncHI1B Plasmids Encoding Efflux Pump
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- Distinct and shared impacts of virulence plasmids on the phenotype and transcriptome in convergent carbapenem-resistant and hypervirulentMicrobiology spectrum · 2026Article
- Characterization of tmexCD-toprJ-positive Klebsiella spp. from pediatric patients in a Chinese hospital.BMC microbiology · 2026Article
- Plasmid-mediated convergence of multidrug resistance and hypervirulence in community-acquired Klebsiella pneumoniae in Tianjin, China.BMC microbiology · 2026Article
- Clonal dissemination of carbapenem-resistant ST477Frontiers in cellular and infection microbiology · 2025Article
- Emergence of Mobilized Tigecycline Resistance Gene ClusterTransboundary and emerging diseases · 2025Article
- Coexistence of plasmid-mediatedMicrobiology spectrum · 2024Article
- Comparative Genomics Revealing the Genomic Characteristics ofTropical medicine and infectious disease · 2024Article
- First Report of Carbapenem-ResistantInfection and drug resistance · 2024Article
- The tigecycline resistance mechanisms in Gram-negative bacilli.Frontiers in cellular and infection microbiology · 2024Review
- Host range of strand-biased circularizing integrative elements: a new class of mobile DNA elements nesting in Gammaproteobacteria.Mobile DNA · 2023Article
- Genome Characterization of Bacteriophage KPP-1, a Novel Member in the SubfamilyMicroorganisms · 2023Article
- Characterization of nontyphoidalFrontiers in cellular and infection microbiology · 2023Article
- Convergence of plasmid-mediated Colistin and Tigecycline resistance inFrontiers in microbiology · 2023Article
- Multiple Copies of Mobile Tigecycline Resistance Efflux Pump Gene ClusterMicrobiology spectrum · 2022Article
- Emergence of a Novel Plasmid-Mediated Tigecycline Resistance Gene Cluster,Microbiology spectrum · 2022Article
- Coexistence ofMicrobiology spectrum · 2022Article
- Emergence of Plasmids Co-Harboring Carbapenem Resistance Genes andFrontiers in cellular and infection microbiology · 2022Article
- Molecular insights into novel environmental strains ofFrontiers in public health · 2022Article
- Mobile Tigecycline Resistance: An Emerging Health Catastrophe Requiring Urgent One Health Global Intervention.Frontiers in microbiology · 2022Review
- Epidemiology ofInfection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline serves as one of the last-resort antibiotics to treat severe infections caused by carbapenem-resistant Enterobacterales. Recently, a novel plasmid-mediated resistance-nodulation-division (RND)-type efflux pump gene cluster,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.